Sulforaphane Inhibits Liver Cancer Cell Growth and Angiogenesis

Abstract

Sulforaphane (SFN) exhibits inhibitory effects in different types of cancers. However, its inhibitory effect on liver cancer remains unknown. This study aimed to determine the therapeutic potential of SFN for the treatment of liver cancer and explore the functional mechanisms underlying the inhibitory effects of SFN. Water-Soluble Tetrazolium salt (WST-1) assay was performed to assess the in vitro effect of SFN on cell proliferation in the human liver cancer cell lines, HepG2 and Huh-7. The mRNA levels of Nrf2 target genes and cell cycle-related genes were determined using quantitative RT-PCR. For assessing the inhibitory effect of SFN in vivo, we injected immortalized liver cancer cells into BALB/c nude mice as a xenograft model. SFN was orally administrated daily after tumor inoculation and continued for thirty-five days until their sacrifices. Nrf2 activation, induced by SFN, was confirmed by mRNA upregulation of HO-1, MRP2, and NQO1 in both the cell lines. Significant inhibition of liver cancer cell proliferation by SFN was shown in vitro in a dose-dependent manner by the downregulation of CCND1, CCNB1, CDK1 and CDK2. In in vivo studies, the administration of SFN significantly reduced the subcutaneous tumor burdens at the end of experiments by suppressing tumor cell proliferation, confirmed by Ki67 immunohistochemical analysis. The mRNA levels of CCND1, CCNB1, CDK1 and CDK2 were also decreased in these SFN-treated xenograft tumors. Moreover, CD34 immunostaining elucidated that the intratumoral neovascularization was markedly attenuated in the SFN-treated xenograft tumors. SFN exerts inhibitory effect on human liver cancer cells with antiangiogenic activity. The earlier version of this study was presented at the meeting of AASLD Liver Learning on Oct 2017.

Keywords: Sulforaphane; Nrf2; Liver cancer; Angiogenesis

Introduction

Hepatocellular carcinoma (HCC) is a highly aggressive form of solid malignancy and is the third cause of cancer-related deaths [1]. The incidence of HCC is rising globally at an accelerated rate [2], making it the fifth most common cancer in men and the seventh most common cancer in women [1,3]. HCC can be treated curatively via surgical resection or liver transplantation if diagnosed during the early stage; however, majority of the HCC patients are diagnosed during the advanced stage; therefore, their median survival times are generally lower than one year, resulting in poor prognosis. A primary reason for poor prognosis in HCC patients is the absence of effective therapies, particularly for the advanced stages. Sorafenib, a multi-kinase inhibitor, is the...
first agent that has demonstrated survival benefits in patients with unresectable advanced HCC [4]. Sorafenib has showed overall survival benefit; however, the response rate is not acceptable in clinical practice because given the several adverse effects of this drug, only few patients were able to continue it. In patients with conditions, such as hand-foot syndrome, severe hypertension, and acute liver injury, more effective therapies are required to improve the prognosis of advanced HCC patients. In addition to a molecular targeted therapy, the potent antitumor activity exerted by certain natural product-derived drugs has been reported for several types of cancers [5,6].

Sulforaphane (SFN), a naturally occurring isothiocyanate derived from cruciferous vegetables, especially broccoli, has been widely used for treating inflammatory diseases. This substance is regarded safe for oral intake because it is not artificially produced and is rarely associated with liver injury. In addition, SFN is a proven, important cancer preventive agent with high activity in some clinical neoplasms, including colorectal cancer [7], urinary bladder cancer [8,9], prostatic cancer [10,11], breast cancer [12,13], thyroid cancer [14,15], and leukemia [16,17]. However, the inhibitory effect of SFN on liver cancer, mainly HCC, remains unknown. In this study, we used two different strains of the human liver cancer cell line in both in vitro and in vivo models and attempted to explore the therapeutic potential of SFN on liver cancer and understand its molecular mechanisms. To our knowledge, this is the first report to clearly demonstrate the efficacy of SFN as an inhibitory agent for liver cancer in “in vivo” model without any remarkable adverse effects.

Materials and Methods

Liver cancer cell lines and reagents

Human liver cancer cell lines of HepG2 and Huh7 were procured from the RIKEN BRC CELL BANK (Ibaraki, Japan). They were maintained as monolayer cultures in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (Both from the RIKEN BRC CELL BANK (Ibaraki, Japan). They were Human liver cancer cell lines and reagents. Liver cancer cell lines and reagents.

Water-Soluble Tetrazolium salt (WST)-1 assay

In order to evaluate the direct effect of SFN on the human liver cancer cell lines, we compared cell proliferation with or without SFN treatment. The human liver cancer cell lines of HepG2 and Huh7 were respectively seeded on uncoated plastic dishes at a density of 1.5 × 10^4 cells/mL. Following overnight culture, the cells were treated for 24 h with different SFN concentrations (0, 5, 10, 20, and 40 µM). Cell proliferation was measured using the WST-1 assay as per the manufacturer’s protocol.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted from the tumor tissue samples using acid guaniidinium thiocyanate-phenol-chloroform extraction. The mRNA levels of HMOX1, ABCC2, NQO1, and cell cycle genes were measured using qPCR with the Applied Biosystems Step One Plus™ Real-Time PCR (Applied Biosystems, Foster City, CA, USA), as described previously [18,19]. Primer sequences were as follows:

- HMOX1, forward 5’-AGTTCTGTATGTGCCCCACAGGCT-3’ and reverse 5’-TTTCGGAGCCCAGGCTGCTCCA-3’;
- ABCC2, forward 5’-GAGCACACGAGAGGATTCT-3’ and reverse 5’-AGCCAAGCTGGTCTCACC-3’;
- NQO1, forward 5’-CAGCTACCGAGAGAATGT-3’ and reverse 5’-GAGTGACGAGCATCAGTG-3’;
- CCND1, forward 5’-CCGTCCAGGAGGAATAGGGC-3’ and reserve 5’-GAATCTCCAGGAGGAATAGGGG-3’;
- CDK2, forward 5’-TTGGTACCCAGCTCTGAAAT-3’ and reverse 5’-GAATCTCCAGGAGGAATAGGGG-3’;
- CDKN1A, forward 5’-AACCTGACGCTGTGACC-3’ and reverse 5’-GTGAGTGGTAGAATGGCTGTA-3’;
- CCNB1, forward 5’-GAACCTGAGCCAGAACCTGA-3’ and reverse 5’-ACAGGTCTTCTCTGCAAGGG-3’;
- CDK1, forward 5’-TTGGATCTATCCCTCCTGG-3’ and reverse 5’-CTCTGGAGTTGAACTGGCTGTA-3’;
- CDK6, forward 5’-ACCTGTGACGCTGTGACC-3’ and reverse 5’-GAGTGAGCCAGTACGATCAGTG-3’.

The cycling conditions were as follows: initial holding stage at 95°C for 20 sec; followed by 40 cycles at 95°C for 3 s and at 60°C for 30 s, followed by the melting curve stage at 95°C for 15 s, at 60°C for 1 min, and at 95°C for 15 s.

Xenograft model

All the animal procedures were performed as per the recommendations of the Guide for Care and Use of Laboratory Animals (National Research Council, USA). The study was approved by the animal facility committee of Nara Medical University (Authorization number: #11639). Six-week-old athymic nude mice (BALB/cSlc-nu/nu) were purchased from Japan SLC, Inc. (Hamamatsu, Shizuoka, Japan) and housed in stainless steel mesh cages under controlled conditions (temperature: 23 ± 3°C, relative humidity: 50 ± 20%, 10–15 air changes/hour, illumination: 12 h/d). The animals were allowed tap water access ad libitum throughout the study period.

For tumor inoculation, 3 × 10^6 cells were suspended in 200 µL medium and Matrigel High Concentration (Corning, Tewksbury, MA, USA; 1:1) and subcutaneously injected into the bilateral flanks of the mice. The tumor dimensions were measured weekly using a caliper, and volumes were calculated using the following formula: 1/2 (W2 × L), where W and L are the measured width and length, respectively. Seven days prior to the inoculation, the mice were given oral administration of SFN at a dose of 50 mg/kg in 0.1 ml saline containing 0.5% DMSO; the mice in the vehicle group were administered an equivalent volume of saline solution containing 0.5% DMSO. The administered SFN dose in this study was adjusted according to previous reports [20-22]. All the mice were sacrificed 5 weeks following the inoculations, and the size of each collected tumor was recorded.

Immunohistochemistry

The cell proliferation ability was assessed by performing immunohistochemical quantification of the Ki-67 [23]. Moreover, tumor angiogenesis was estimated using CD 34
immunohistochemistry. In addition, a quantitative analysis of the immunopositive area was performed using Adobe Photoshop software (Adobe Systems Inc., USA).

Statistical analyses
Results are presented as mean ± standard deviation values and analysed using Student’s t-test for the unpaired data (SPSS version 22; IBA, Armonk, NY, USA). p<0.05 was considered statistically significant.

Results
SFN suppresses HepG2 cell growth by causing cell cycle arrest
In order to explore the inhibitory effect of SFN on the human liver cancer cell lines, WST assay was performed. The WST assay examined the effect of SFN on cell proliferation of the HepG2 cells. SFN significantly inhibited cell proliferation of the HepG2 cells in a dose-dependent manner (Figure 1A). Thereafter, we evaluated the gene expression of HMO1, ABCC2, and NQO1 in the HepG2 cells to determine whether Nrf2 partly mediated the inhibiting effect of SFN, a known Nrf2 agonist. All these were Nrf2 target genes and were significantly upregulated in the SFN-treated group (Figure 1B). Given that growth inhibition of cancer cells is usually associated with cell cycle arrest, we investigated the effect of SFN on the expression of the cell cycle-related genes, CCND1, CCNB1, CDK1, CDK2, and CDKN1A in the HepG2 cell. Compared with those of the controls, the mRNA expression levels of CCND1, CCNB1, CDK1 and CDK2 in the HepG2 cells were distinctly lower in the SFN-treated group (Figure 2). Similarly, SFN significantly inhibited cell proliferation of the HuH7 cells in a dose-dependent manner. The Nrf2 target genes were significantly upregulated in the SFN-treated group. The mRNA expression levels of CCND1, CCNB1, CDK1, and CDK2 in the HuH7 cells were substantially lower in the SFN-treated group (Supplementary Figure S1).

SFN suppresses liver cancer growth in in vivo xenografted model
Given the in vitro inhibitory effect of SFN on human liver cancer cell growth, we further evaluated the suppressive effect of SFN on in vivo tumor growth of xenografted liver cancer in athymic nude mice. At the end of the experiments, both the mean tumor volumes and weights were significantly lower in the SFN-treated mice than in the control mice (Figure 3A). HepG2 cell-derived xenograft tumors of the control mice aggressively grew following inoculation, while the tumors in the mice treated with SFN exhibited modest growth (Figures 3B and 3C). However, body weight, an indicator of the general health of animals, did not show a significant difference between these two groups at the sacrifices (Supplementary Figures S2 and S3). In addition, there were no significant changes of the serum level of alanine aminotransferase (ALT), albumin, and total bilirubin in the

Figure 1 Suppressive effect of sulforaphane on HepG2 cell proliferation in vitro. (A) WST assay revealed that sulforaphane suppressed the proliferation of the HepG2 cells in a dose-dependent manner. (B) Regulation of Nrf2 target genes in the HCC cell lines. Relative mRNA expression levels in HepG2 were measured using quantitative RT-PCR (qRT-PCR). GAPDH was used as an internal control. Relative mRNA expression levels of Nrf2 target genes in HepG2 cells were significantly higher in the SFN treated group. Sulforaphane caused cell cycle arrest in HCC. Relative mRNA expression levels of cell cycle-related markers in the HepG2 cells were significantly lower in the SFN-treated group (*; p<0.05, **; p<0.01).
course of this experiment in each group (Supplementary Table S1). These observations implicate that the indicated dose of SFN would rarely cause any liver injury in mice, supporting that it could be a safe and effective agent for liver cancer therapy at least in the xenograft tumor model. Similar results were shown in the experiment of the Huh7 cell lines (Supplementary Figure S4).

**SFN diminishes the proliferation of the xenografted tumor cells**

We assessed the tumor cell viability using Ki-67 immunohistochemistry. The number of Ki-67 immuno-positive cells in the tumor of the SFN-treated group was significantly lower than that in the tumor of the control group (Figures 4A-4C). Using this quantitative assessment, we found that SFN effectively diminished Ki-67 immunopositive cell proliferation in the xenograft tumors. Along with these suppressed features of cell proliferation, the mRNA expression levels of CCND1, CCNB1, CDK1 and CDK2, cell cycle regulators, were considerably down regulated in the subcutaneous tumors of SFN-treated mice. Additionally, to determine the effect of SFN on tumor cell apoptosis, we performed immunohistochemical evaluation of caspase 3. The number of caspases 3 immuno-positive cells in the tumor of the SFN-treated group was significantly larger than that of the control group (Supplementary Figure S5).

**SFN regulates the Nrf2 target genes**

In order to determine the antitumor effect of SFN directly through the Nrf2 signaling cascade, we further evaluated the Nrf2 target gene expression levels in the xenograft tumors, such as HMOX1, ABCC2, and NQO1. ABCC2 and NQO1 showed significant upregulation in the SFN-treated group, suggesting that SFN actually regulated the Nrf2 target genes in the subcutaneously grafted liver cancer (Figure 5).

**SFN suppresses intra-tumoral angiogenesis**

Angiogenesis is a physiologic process that is important for tissue growth, remodeling, and wound healing; however, it is also a prerequisite for tumor growth and metastasis [24]. We evaluated the intratumoral cell angiogenesis using CD34.
immunohistochemistry. The immunopositive area in the tumor of the SFN-treated group was lower than that of the tumor in the control group (Figure 6A). Qualitative assessment showed that the CD34 immunopositive area in the tumors of the SFN treated group was significantly smaller than that in the tumors of the control group (Figure 6B).

Thus, we successfully demonstrated that SFN exerted an inhibitory effect on the human liver cancer cell lines. Furthermore, we found that SFN inhibited the proliferation and angiogenesis of the human liver cancer cell lines, partially mediated by the Nrf2 signalling cascade.

Discussion and Conclusion

SFN, a dietary isothiocyanate that is present in broccoli and cauliflower, has been widely used for treating inflammatory diseases, and recent studies have demonstrated its inhibitory activities in tumor cell lines and animals models [11,12,25-27]. Moreover, SFN from broccoli sprouts has already been evaluated in a phase I clinical trial that demonstrated a good safety profile of SFN [28], a phase II clinical trial that aims to treat patients with recurrent prostate cancer is currently ongoing (ClinicalTrials.gov, NCT01228084). These reports indicate that SFN is a potential inhibitory agent for treating cancer. However, its inhibiting effect on liver cancer is still unclear. In the present study, we demonstrated that SFN considerably suppressed the growth of human liver cancer cells in vitro and in vivo.

Actually, several studies have been reported for the efficacy of SFN as an inhibitory agent against the HepG2 cell line [29-31]. However, these reports evaluated the effect of SFN in the “ex vivo” or “in vitro” study. Our study assessed the inhibitory effect of SFN in the “in vivo” study using the xenograft model which was simple and would reflect the clinical treatment.

Our data showed that SFN stimulated the Nrf2 signalling cascade in the liver cancer cell lines, stimulating the SFN-treated liver cancer cells to arrest their proliferation, accompanied by the inhibition of CCND1, CCNB1, CDK1 and CDK2 mRNA expression levels. Several reports indicated that sulforaphane arrested the cell cycle by decreasing retinoblastoma (Rb) phosphorylation in diverse cancers [32-34]. Moreover, SFN had a substantial in vivo suppressive effect on tumor growth in xenografted liver cancer. Similar to that in in vitro studies, the Nrf2 signalling cascade was activated in the tumors of mice treated with SFN. Using some immunohistochemical findings, we successfully showed that SFN effectively suppresses cell proliferation and angiogenesis in xenograft tumors. These results suggest that SFN exerts an inhibitory effect on cell proliferation and angiogenesis of human liver cancer. In this study, the IC50 value of sulforaphane on HepG2 cells was 22 µM (Figure 1). Biotechnical sheet of SFN shows that the IC50 value of this substance on HepG2 cells is to be 24.85 µM, and these concentrations are similar to each other. Furthermore, the IC50 value of sulforaphane on Huh 7 cells were 20 µM. We also found a paper in which similar results were shown concerning of the IC50 of SFN on Huh7 cells [35].

Clinical study demonstrates a dose-dependent inhibitory effect for sulforaphane in cancer cells [36]. We selected the dose of SFN which was used in the previous reports. Even though it is difficult to predict whether micromolar concentrations of SFN are achievable in humans as pharmacokinetics of this agent, previous studies have estimated that a hundred grams of broccoli could yield up to 40 µmol of SFN [37,38]. A more recent pharmacokinetics study involving four human volunteers receiving single dose of 200 µmol of broccoli sprout indicated that isothiocyanates (ITCs) were absorbed rapidly and reached to the peak concentrations of 0.943-2.27 µmol in plasm, serum and erythrocytes 1 hour after ingestion of broccoli extract [39]. Of course, carefully designed pharmacokinetics studies of pure SFN are necessary to determine its ideal concentration.

In normal physiological conditions, Nrf2 is anchored in the cytoplasm by Kelch-like ECH-associated protein 1 (Keap1), which also mediates proteasomal degradation of Nrf2. Oxidative and electrophilic stresses cause dissociation of Nrf2 from Keap1 and lead Nrf2 to translocate into the nucleus where it can bind to the Antioxidant Response Element (ARE), a cis-acting element on the promoter of multiple cytoprotective genes. Binding to ARE results in transactivation of these ARE-bearing genes [40,41]. SFN is known as the Nrf2 agonist [42,43]. Nrf2 activation results in that Nrf2 moves the nucleus where it can bind to the Antioxidant

Figure 6 Sulforaphane suppresses angiogenesis in HepG2. (A) Representative pictures of HepG2-grafted subcutaneous tumors immunologically stained with CD34. (B) Quantification of CD34 immuno-positive areas. Quantitative analyses of immune-positive area were conducted using an image analyzing software. The CD34 immuno-positive area was significantly diminished in the SFN-treated group (**: p<0.01).
Response Element (ARE). So, the total amount of Nrf2 is not increased by the stimulation of SFN. Our study showed that the expression of Nrf2 was not different between groups (data not shown). That is the reason why we demonstrated the evidence of the Nrf2 activation by assessing the expression of corresponding downstream genes.

It is known that SFN activates Nrf2 and acts in part on the Keap1/Nrf2 pathway to regulate several cytoprotective genes [44]. It has been widely accepted that activating Nrf2 protects the cell homeostasis from reactive oxygen species (ROS) and the metabolites of carcinogens. In contrast, Nrf2 signalling can reportedly be compromised by cancer cells as the adaptive mechanism that alleviates ROS and electrophilic burdens within the tumor microenvironment, enabling cancer cell survival [45]. Moreover, the tumorigenic potential of Nrf2 was reported in the Diethyl Nitrosamine (DEN)-induced murine HCC model using Nrf2 KO mice [46]. These reports may conflict the current findings. However, Nrf2, the master regulator of cellular redox status, has also been reported to have a biphasic response in other studies as a potential risk factor in its application for cancer treatment. Although several future studies are necessary to confirm the mechanism of Nrf2 in malignant neoplasm, we speculate that Nrf2 could exert a suppressive effect on cell proliferation during early-stage liver cancer, while Nrf2 may have a progressive effect during the advanced stage. In the previous study, SFN inhibited thyroid cancer cell growth and invasiveness through repressing phosphorylation of Akt, enhancing p21 expression by the activation of Erk and p38 signalling cascades, and promoting mitochondrial-mediated apoptosis via reactive oxygen species (ROS)-dependent pathway [14]. Probably, SFN exerts an inhibitory effect on cell proliferation of human liver cancer by inducing apoptosis. Moreover, our findings suggest that SFN exerts an inhibitory effect on cell angiogenesis of human liver cancer, partially mediated by the Nrf2 cascade.

Nrf2 activators are considered effective for managing disorders associated with the accumulation of oxidative stress, such as cardiovascular diseases [47], diabetic complications [48], neurodegenerative disorders [49], and several cancers [50-53]. In fact, we did not perform in vivo and in vitro evaluations for the ROS degree of human hepatic cancer cells in this study. Future studies should attempt to clarify the association between ROS and the antitumor effect of SFN on liver cancer.

In sum, we showed that SFN suppressed the proliferation of liver cancer cells and induced cell cycle arrest. Thereafter, we demonstrated the inhibitory effect of SFN on liver cancer tumor angiogenesis and tumor growth during its initial stage. Thus, SFN could hold a high clinical potential for preventing liver cancer in the future.

Acknowledgments

The authors are grateful to the staff of the animal facility of Nara Medical University. This study was supported in part by a grant-in-aid for research from Nara Medical University. The earlier version of this study was presented at the meeting of AASLD Liver Learning on Oct 2017.

Authors’ Contributions

Concept and design: SS, KM, HY. Performing experiments: SS, KM, MF, NS, YS, KS, KK, AM, YO, JY, HY. Writing of article: SS. Editing of article: KM. Data analysis: MF, TN, MK, HK, TA. All the authors have seen and approved the final version of this manuscript.

References


13 Clulow JA, Storch EM, Lanyon-Hogg T, Kalesh KA, Jones LH, et al. (2017) Competition-based, quantitative chemical proteomics in...


